Skip to main content
OpenTrials

Clinical trial condition

Marginal Zone Lymphoma

Explore clinical trials studying Marginal Zone Lymphoma. Study availability and eligibility vary by location and protocol.

114 public trials 41 recruiting studies
Refine in advanced search Browse all conditions

Marginal Zone Lymphoma trial results

Active, Not Recruiting

A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma

NCT04416451

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • City of Hope Cancer Center (Data collection only) Duarte, California, United States
  • Memorial Sloan Kettering Basking Ridge (All Protocol Activities) Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth (All protocol activities) Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen (All protocol Activities) Montvale, New Jersey, United States
View Trial Details
Active, Not Recruiting

A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)

NCT03162536

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Chronic Disease, +41 more
Locations
  • Mayo Clinic Hospital ( Site 0140) Scottsdale, Arizona, United States
  • UCLA Hematology & Oncology ( Site 0017) Los Angeles, California, United States
  • Colorado Blood Cancer Institute ( Site 0225) Denver, Colorado, United States
  • University of Michigan ( Site 0018) Ann Arbor, Michigan, United States
View Trial Details
Active, Not Recruiting

Copanlisib and Rituximab in Marginal Zone Lymphoma Patients

NCT03474744

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • Med. Uni Wien AKH, Klinische Abteilung für Onkologie, Innere Medizin I Vienna, Austria
  • St. Josef-Hospital, Medizinische Klinik I Bochum, Germany
  • Johanniter GmbH, Johanniter-Krankenhaus Bonn, Germany
  • ÜBAG MVZ Dr. Vehling-Kaiser GmbH Dingolfing Dingolfing, Germany
View all 18 locations
View Trial Details
Active, Not Recruiting

Obinutuzumab in Marginal Zone Lymphoma

NCT03322865

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • Augusta-Kranken-Anstalt gGmbH Bochum, Germany
  • University Hospital Essen Essen, Germany
  • Universitätsklinikum Freiburg Freiburg im Breisgau, Germany
  • Universitätsmedizin Georg-August-University Göttingen, Germany
View Trial Details
Active, Not Recruiting

Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells

NCT04911478

Conditions
Diffuse Large B Cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +14 more
Locations
  • Blood and Marrow Transplant Program Palo Alto, California, United States
  • Norton Cancer Institute Louisville, Kentucky, United States
  • Baylor Scott & White Research Institute Dallas, Texas, United States
  • MD Anderson Caner Center Houston, Texas, United States
View Trial Details
Active, Not Recruiting

MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas

NCT03697512

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +11 more
Locations
  • CHU UCL Namur / site Godinne Yvoir, Belgium
  • CHU de Tours - Hôpital Bretonneau Tours, Cedex 01, France
  • CHU de Montpellier Montpellier, Cedex 05, France
  • CHU d'Estaing Clermont-Ferrand, Cedex 1, France
View all 36 locations
View Trial Details
Active, Not Recruiting

Study of Acalabrutinib and Tafasitamab in MZL Patients

NCT04646395

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • University of Wien Vienna, Austria
  • ASST Spedali Civili di Brescia Brescia, Italy
  • Fondazione IRCCS - Istituto Nazionale dei Tumori Milan, Italy
  • Fondazione IRCCS Cà Granda-Ospedale Maggiore Policlinico Milan, Italy
View Trial Details
Active, Not Recruiting

Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom

NCT02952508

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Central Nervous System Lymphoma, +36 more
Locations
  • Cellectar Biosciences site Los Angeles, California, United States
  • Cellectar Biosciences site Redlands, California, United States
  • Cellectar Biosciences site Washington D.C., District of Columbia, United States
  • Cellectar Biosciences site Jacksonville, Florida, United States
View all 52 locations
View Trial Details
Active, Not Recruiting

Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma

NCT05783596

Conditions
Follicular Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +12 more
Locations
  • Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Columbia University Irving Medical Center New York, United States
  • Mount Sinai Medical Center New York, United States
View Trial Details

Related conditions